Telomir Pharmaceuticals’ lead drug candidate, Telomir-1, has demonstrated significant anti-cancer effects in preclinical studies involving aggressive prostate cancer models. In these studies, Telomir-1 reduced tumor size by 50% and provided protection against chemotherapy-induced toxicity.
Beyond oncology, Telomir-1 is being evaluated for age-related diseases such as age-related macular degeneration (AMD) and Wilson’s disease, a rare disorder affecting copper metabolism. The company plans to submit an Investigational New Drug (IND) application by the end of the year, aiming to advance Telomir-1 into clinical trials. Click for More Details
